Adverum Biotechnologies Inc (ADVM)

Adverum Biotechnologies Inc Borsa (ADVM) Ultime notizie

Down -19.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)

Zacks Investment Research

Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year?

Zacks Investment Research

Absci (ABSI) to Report Q1 Earnings: Here's What to Expect

Zacks Investment Research

PetIQ (PETQ) Gears Up to Report Q1 Earnings: What's in Store?

Zacks Investment Research

Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?

Zacks Investment Research

ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?

Zacks Investment Research

Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?

Zacks Investment Research

Adverum Biotechnologies to Participate in Upcoming May Investor Conferences

GlobeNewswire Inc.

Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks Investment Research

Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

GlobeNewswire Inc.

Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?

Zacks Investment Research

Down -24.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)

Zacks Investment Research

Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year?

Zacks Investment Research

How Adverum (ADVM) Stock Stands Out in a Strong Industry

Zacks Investment Research

Down -28.72% in 4 Weeks, Here's Why Adverum Biotechnologies (ADVM) Looks Ripe for a Turnaround

Zacks Investment Research

Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)

Zacks Investment Research

Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?

Zacks Investment Research

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

GlobeNewswire Inc.

Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference

GlobeNewswire Inc.

Wall Street Breakfast: The Week Ahead

Seeking Alpha

Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD

GlobeNewswire Inc.

Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga

Adverum Biotechnologies Announces $127.5 Million Private Placement Financing

GlobeNewswire Inc.

Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

GlobeNewswire Inc.

Here's Why You Should Invest in Adverum (ADVM) Stock Now

Zacks Investment Research

Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

GlobeNewswire Inc.

Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference

GlobeNewswire Inc.